Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Box

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
The New England Journal of Medicine|May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVPeter Ferenci, David Bernstein, Jacob Lalezari, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
The New England Journal of Medicine|May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVPeter Ferenci, David Bernstein, Jacob Lalezari, et al.
Pageof 4